20 November 2026
by Ferdous Al-Faruque

This Week at FDA: Overton nomination pulled, FDA promotes international reliance, and more

Week-FDA-RF-Dept-380x215.png

Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical device regulation, and what we’re reading from around the web. This week, the Trump administration withdrew its FDA commissioner nominee at the eleventh hour, FDA announced a program to help sponsors market products in other countries, and announced several firsts in product approvals.

The White House rescinded its nomination of White House healthcare policy advisor Heidi Overton to lead the Food and Drug Administration (FDA) the night before a vote in the Senate Health, Education, Labor and Pensions (HELP) committee, conceding they did not have sufficient support in Congress. Reuters reported that the administration is now weighing Sen. Roger Marshall (R-KS), who recently lost his reelection bid, as a possible replacement, according to two anonymous sources.

As international regulatory reliance has continued to gain momentum, FDA announced it is launching a Global Reliance Disclosure Program (GRDP) that it says will "fundamentally transform how the FDA's regulatory drug and biologic approval decisions are leveraged by health authorities around the world." The agency said the program will allow it to share minimally redacted approval packages with sponsors, who can then take those documents to other regulators, potentially reducing the need to duplicate product evaluations.

FDA published another batch of draft product-specific guidances (PSGs) for sponsors developing generic drugs and generating evidence for abbreviated new drug applications (ANDAs). The latest batch includes 24 PSGs for products with no approved ANDAs, 15 new PSGs and 14 revised PSGs, and 11 PSGs for complex products, bringing the total number of PSGs published this year to 268.

FDA announced it is hosting a virtual information session on generic drug research needs and opportunities for fiscal year 2027 on 10 December. Agency officials plan to use the opportunity to discuss how specific research may help accelerate the development of generic drugs and expand patient access to such medications.

FDA also announced it has modified its isotretinoin iPLEDGE Risk Evaluation and Mitigation Strategy (REMS). The agency said the modifications are intended to minimize burden on patients, prescribers, and pharmacies while maintaining the safe use of the drug for severe and recalcitrant acne.

Drugs and Biologics

Sanofi subsidiary Genzyme's Infilbray (venglustat) was approved by FDA as the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3), a rare inherited condition where the body cannot properly break down certain fatty substances called glucosphingolipids. The drug was approved for adults and children weighing at least 15 kg (approximately 33 pounds) with the disease, and the agency touted its ability to cross the blood-brain barrier to reduce the accumulation of harmful substances in the body and brain.

Similarly, Beren Therapeutics subsidiary Mandos' injection Lembaz (adrabetadex) was approved by FDA as the first treatment for a severe form of Niemann-Pick disease type C (NPC), a rare inherited lysosomal storage disorder affecting an estimated 1 in 150,000 people, in which they are unable to properly process cholesterol and other fats inside cells. More specifically, the drug was approved to reduce the risk of death in adult and pediatric patients who weigh at least 7 kg (about 15 pounds) and whose neurological symptoms began before age 6, also known as infantile-onset NPC.

Roche subsidiary Genentech's oral estrogen receptor antagonist Wilserdly (giredestrant) was approved by FDA in combination with everolimus to treat adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated locally advanced or metastatic breast cancer. The agency noted that the treatment is based on diagnoses made with an FDA-authorized test, in which the disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting.

Genentech's injection, Gazyva (obinutuzumab), was also approved as the first treatment for adults with primary membranous nephropathy at risk of disease progression. The drug is intended to induce remission of proteinuria and was already approved by FDA to treat certain cancers, active lupus nephritis, and childhood-onset idiopathic nephrotic syndrome.

FDA published a guidance snapshot and podcast discussing its draft guidance entitled, 'Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing.' The agency said the snapshot and podcast are intended to promote further dialogue with stakeholders on an important regulatory topic and elicit public feedback.

The Center for Biologics Evaluation and Research (CBER) published several updated Standard Operating Policies and Procedures (SOPPs), including one on fast-track development programs and another on management of regenerative medicine advanced therapy products. Both SOPPs incorporate changes reflecting a reorganization at the center. The center also published an updated SOPP on breakthrough therapy products, revised in April to reflect new procedures and remove redundant steps related to holds and weekly reports.

FDA launched a new drug quality monitoring initiative entitled Enhanced Approach for Sampling and Testing (EAST). The agency said the initiative combines modern screening techniques with traditional testing methods to allow it to test more drugs and identify potential quality issues faster.

FDA also announced it has established the CBER Safety Council (CSC), a new governance body within the biologics center dedicated to strengthening post-market safety oversight for products such as cell and gene therapies, vaccines, and blood and blood products. The agency said the council was created from CBER's Safety Working Group (SWG) and will operate separately from other CBER product offices, reporting directly to the CBER Director to ensure that post-market safety oversight for all regulated biological products is conducted through an accountable, dedicated, cross-functional team.

Medtech

An early alert was issued for certain Outset Medical Tablo consoles and TabloCarts with prefiltration drawers due to reports of overheating at the connection between the power cord and the products' power inlets, which could burn users and cause delayed or missed treatments. FDA said the company has issued a recall to customers with updated use instructions.

B. Braun Medical's recall for certain Caresite Micro Luer Access Devices also received an early alert from FDA due to customer complaints that the piston, located within the female end of the device, remained depressed after disconnecting the luer from the access site due to a lack of lubrication. If the valve on the device remains open due to the issue after it has been disconnected, it could lead to leakage of blood, intravenous fluids, and medications, as well as air entering the pathway, causing an embolism, all of which may cause serious injuries or death.